SARS-CoV-2 rapid antigen testing of symptomatic and asymptomatic individuals on the University of Arizona campus

David T. Harris; Michael Badowski; Brandon Jernigan; Ryan Sprissler; Taylor Edwards; Randall Cohen; Stephen Paul; Nirav Merchant; Craig C. Weinkauf; Christian Bime; Heidi E. Erickson; Billie Bixby; Sairam Parthasarathy; Sachin Chaudhary; Bhupinder Natt; Elaine Cristan; Tammer El Aini; Franz Rischard; Janet Campion; Madhav Chopra; Michael Insel; Afshin Sam; James L. Knepler; Kenneth Knox; Jerrod Mosier; Catherine Spier; Michael D. Dake

doi:10.3390/biomedicines9050539

SARS-CoV-2 rapid antigen testing of symptomatic and asymptomatic individuals on the University of Arizona campus

David T. Harris, Michael Badowski, Brandon Jernigan, Ryan Sprissler, Taylor Edwards, Randall Cohen, Stephen Paul, Nirav Merchant, Craig C. Weinkauf, Christian Bime, Heidi E. Erickson, Billie Bixby, Sairam Parthasarathy, Sachin Chaudhary, Bhupinder Natt, Elaine Cristan, Tammer El Aini, Franz Rischard, Janet Campion, Madhav ChopraMichael Insel, Afshin Sam, James L. Knepler, Kenneth Knox, Jerrod Mosier, Catherine Spier, Michael D. Dake

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

SARS-CoV-2, the cause of COVID19, has caused a pandemic that has infected more than 80 M and killed more than 1.6 M persons worldwide. In the US as of December 2020, it has infected more than 32 M people while causing more than 570,000 deaths. As the pandemic persists, there has been a public demand to reopen schools and university campuses. To consider these demands, it is necessary to rapidly identify those individuals infected with the virus and isolate them so that disease transmission can be stopped. In the present study, we examined the sensitivity of the Quidel Rapid Antigen test for use in screening both symptomatic and asymptomatic individuals at the University of Arizona from June to August 2020. A total of 885 symptomatic and 1551 asymptomatic subjects were assessed by antigen testing and real-time PCR testing. The sensitivity of the test for both symptomatic and asymptomatic persons was between 82 and 90%, with some caveats.

Original language	English (US)
Article number	539
Journal	Biomedicines
Volume	9
Issue number	5
DOIs	https://doi.org/10.3390/biomedicines9050539
State	Published - May 2021

Keywords

Asymptomatic
Diagnostic screening
PCR
Rapid antigen test
SARS-CoV-2

ASJC Scopus subject areas

Medicine (miscellaneous)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.3390/biomedicines9050539

Cite this

Harris, D. T., Badowski, M., Jernigan, B., Sprissler, R., Edwards, T., Cohen, R., Paul, S., Merchant, N., Weinkauf, C. C., Bime, C., Erickson, H. E., Bixby, B., Parthasarathy, S., Chaudhary, S., Natt, B., Cristan, E., El Aini, T., Rischard, F., Campion, J., ... Dake, M. D. (2021). SARS-CoV-2 rapid antigen testing of symptomatic and asymptomatic individuals on the University of Arizona campus. Biomedicines, 9(5), Article 539. https://doi.org/10.3390/biomedicines9050539

Harris, DT, Badowski, M, Jernigan, B, Sprissler, R, Edwards, T, Cohen, R, Paul, S, Merchant, N, Weinkauf, CC, Bime, C, Erickson, HE, Bixby, B, Parthasarathy, S, Chaudhary, S, Natt, B, Cristan, E, El Aini, T, Rischard, F, Campion, J, Chopra, M, Insel, M, Sam, A, Knepler, JL, Knox, K, Mosier, J, Spier, C & Dake, MD 2021, 'SARS-CoV-2 rapid antigen testing of symptomatic and asymptomatic individuals on the University of Arizona campus', Biomedicines, vol. 9, no. 5, 539. https://doi.org/10.3390/biomedicines9050539

@article{1f968102aa964d759d40feb9246ebccd,

title = "SARS-CoV-2 rapid antigen testing of symptomatic and asymptomatic individuals on the University of Arizona campus",

abstract = "SARS-CoV-2, the cause of COVID19, has caused a pandemic that has infected more than 80 M and killed more than 1.6 M persons worldwide. In the US as of December 2020, it has infected more than 32 M people while causing more than 570,000 deaths. As the pandemic persists, there has been a public demand to reopen schools and university campuses. To consider these demands, it is necessary to rapidly identify those individuals infected with the virus and isolate them so that disease transmission can be stopped. In the present study, we examined the sensitivity of the Quidel Rapid Antigen test for use in screening both symptomatic and asymptomatic individuals at the University of Arizona from June to August 2020. A total of 885 symptomatic and 1551 asymptomatic subjects were assessed by antigen testing and real-time PCR testing. The sensitivity of the test for both symptomatic and asymptomatic persons was between 82 and 90%, with some caveats.",

keywords = "Asymptomatic, Diagnostic screening, PCR, Rapid antigen test, SARS-CoV-2",

author = "Harris, {David T.} and Michael Badowski and Brandon Jernigan and Ryan Sprissler and Taylor Edwards and Randall Cohen and Stephen Paul and Nirav Merchant and Weinkauf, {Craig C.} and Christian Bime and Erickson, {Heidi E.} and Billie Bixby and Sairam Parthasarathy and Sachin Chaudhary and Bhupinder Natt and Elaine Cristan and {El Aini}, Tammer and Franz Rischard and Janet Campion and Madhav Chopra and Michael Insel and Afshin Sam and Knepler, {James L.} and Kenneth Knox and Jerrod Mosier and Catherine Spier and Dake, {Michael D.}",

note = "Funding Information: We wish to acknowledge the invaluable participation of David Salafsky and Michael Stilson from the University of Arizona Campus Health, without whom it would not have been possible to conduct these studies. In addition, we acknowledge all the staff involved with biospecimen collections as well as the technicians who toiled many hours to analyze the samples once they arrived in the laboratory. Finally, we thank all of the subjects for their participation. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = may,

doi = "10.3390/biomedicines9050539",

language = "English (US)",

volume = "9",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "5",

}

TY - JOUR

T1 - SARS-CoV-2 rapid antigen testing of symptomatic and asymptomatic individuals on the University of Arizona campus

AU - Harris, David T.

AU - Badowski, Michael

AU - Jernigan, Brandon

AU - Sprissler, Ryan

AU - Edwards, Taylor

AU - Cohen, Randall

AU - Paul, Stephen

AU - Merchant, Nirav

AU - Weinkauf, Craig C.

AU - Bime, Christian

AU - Erickson, Heidi E.

AU - Bixby, Billie

AU - Parthasarathy, Sairam

AU - Chaudhary, Sachin

AU - Natt, Bhupinder

AU - Cristan, Elaine

AU - El Aini, Tammer

AU - Rischard, Franz

AU - Campion, Janet

AU - Chopra, Madhav

AU - Insel, Michael

AU - Sam, Afshin

AU - Knepler, James L.

AU - Knox, Kenneth

AU - Mosier, Jerrod

AU - Spier, Catherine

AU - Dake, Michael D.

N1 - Funding Information: We wish to acknowledge the invaluable participation of David Salafsky and Michael Stilson from the University of Arizona Campus Health, without whom it would not have been possible to conduct these studies. In addition, we acknowledge all the staff involved with biospecimen collections as well as the technicians who toiled many hours to analyze the samples once they arrived in the laboratory. Finally, we thank all of the subjects for their participation. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/5

Y1 - 2021/5

N2 - SARS-CoV-2, the cause of COVID19, has caused a pandemic that has infected more than 80 M and killed more than 1.6 M persons worldwide. In the US as of December 2020, it has infected more than 32 M people while causing more than 570,000 deaths. As the pandemic persists, there has been a public demand to reopen schools and university campuses. To consider these demands, it is necessary to rapidly identify those individuals infected with the virus and isolate them so that disease transmission can be stopped. In the present study, we examined the sensitivity of the Quidel Rapid Antigen test for use in screening both symptomatic and asymptomatic individuals at the University of Arizona from June to August 2020. A total of 885 symptomatic and 1551 asymptomatic subjects were assessed by antigen testing and real-time PCR testing. The sensitivity of the test for both symptomatic and asymptomatic persons was between 82 and 90%, with some caveats.

AB - SARS-CoV-2, the cause of COVID19, has caused a pandemic that has infected more than 80 M and killed more than 1.6 M persons worldwide. In the US as of December 2020, it has infected more than 32 M people while causing more than 570,000 deaths. As the pandemic persists, there has been a public demand to reopen schools and university campuses. To consider these demands, it is necessary to rapidly identify those individuals infected with the virus and isolate them so that disease transmission can be stopped. In the present study, we examined the sensitivity of the Quidel Rapid Antigen test for use in screening both symptomatic and asymptomatic individuals at the University of Arizona from June to August 2020. A total of 885 symptomatic and 1551 asymptomatic subjects were assessed by antigen testing and real-time PCR testing. The sensitivity of the test for both symptomatic and asymptomatic persons was between 82 and 90%, with some caveats.

KW - Asymptomatic

KW - Diagnostic screening

KW - PCR

KW - Rapid antigen test

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85106651472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106651472&partnerID=8YFLogxK

U2 - 10.3390/biomedicines9050539

DO - 10.3390/biomedicines9050539

M3 - Article

AN - SCOPUS:85106651472

SN - 2227-9059

VL - 9

JO - Biomedicines

JF - Biomedicines

IS - 5

M1 - 539

ER -

SARS-CoV-2 rapid antigen testing of symptomatic and asymptomatic individuals on the University of Arizona campus

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this